Target intelligence / Profile preview

Gastric mucus and mucosal glycoproteins (MUC5AC/MUC6)

Target
MUC5AC/MUC6
Molecular classification
Glycoprotein, Mucin family, Extracellular matrix component
01

Overview

Gastric mucus and mucosal glycoproteins, primarily Mucin-5AC (MUC5AC) and Mucin-6 (MUC6), constitute the primary physical barrier protecting the stomach lining from autodigestion by gastric acid and pepsin (StatPearls, 2023). MUC5AC is secreted by surface mucous cells, while MUC6 is produced by mucous neck cells, together forming a viscoelastic gel that traps bicarbonate ions to maintain a near-neutral pH at the epithelial surface (PubMed, PMID: 15153509). In pathological states such as peptic ulcer disease or Helicobacter pylori infection, the integrity of this glycoprotein matrix is often compromised, leading to mucosal erosion and inflammation (NIH, 2022). Therapeutic agents known as cytoprotective drugs, including sucralfate and rebamipide, interact with these glycoproteins to reinforce the barrier or stimulate their synthesis (PubChem, CID 5284595). Sucralfate, for instance, forms a polyanionic complex that binds to positively charged proteins and glycoproteins within ulcerated tissue, creating a protective bandage against further chemical injury (StatPearls, 2023).

Other names
Gastric mucinGastric mucus barrierMucin-5ACMucin-6Surface mucous cell mucinGlandular mucous cell mucin
02

Mechanism of action

Binding to mucosal glycoproteins to form a protective physical barrier; stimulation of endogenous prostaglandin-mediated mucus and bicarbonate secretion; enhancement of glycoprotein synthesis and sulfation to improve gel viscosity (StatPearls, 2023; PubMed, PMID: 15153509).

03

Biological functions

Mucosal protectionLubrication of the gastric wallPhysical barrier against gastric acid and pepsinMaintenance of a pH gradient via bicarbonate trappingEntrapment and clearance of pathogens
04

Disease associations

Peptic ulcer diseaseGastritisGastric cancerGastroesophageal reflux disease (GERD)Helicobacter pylori infection
05

Safety considerations

Reduced absorption of co-administered drugs (e.g., fluoroquinolones, digoxin, warfarin) due to physical bindingConstipationBezoar formation in patients with impaired gastric motilityPotential for aluminum accumulation in patients with chronic renal failure (specific to sucralfate)
06

Interacting drugs

Sucralfate

7 more in the full profile.

07

Biomarkers

MUC5AC expression levelsMUC6 expression levelsGastric mucus layer thicknessMucin sulfation patternsHexosamine concentration in gastric juice

Beyond the preview

Go deeper on Gastric mucus and mucosal glycoproteins (MUC5AC/MUC6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gastric mucus and mucosal glycoproteins (MUC5AC/MUC6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call